Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.
Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.
With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.
U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (liso-cel, BREYANZI) for Large B-cell Lymphoma
Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).
U.S. Food and Drug Administration Approves Umbralisib (UKONIQ) for Marginal Zone Lymphoma and Follicular Lymphoma
Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely?
As of January 2021, there are two COVID-19 vaccines that have been approved by the…
Ask the Doctor: Does CHOP chemotherapy remain the go-to frontline treatment for peripheral T-cell lymphoma or have new therapies been added in combination to this regimen?
Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically…
U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.
Ask the Doctor: What is the role of checkpoint inhibitors for the treatment of Hodgkin lymphoma (HL)?
Checkpoint inhibitors are a new class of drugs used by the immune system to determine…